Latest Typical antipsychotics Stories
( ) ALISO VIEJO, Calif., July 2, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA®, further expanding the intellectual property portfolio for the company's lead commercial asset. This asset is a dual sigma-1 and NMDA receptor modulator that is approved for the treatment of pseudobulbar affect (PBA), and is in clinical development for...
ALISO VIEJO, Calif., June 5, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced details of its Patient Assistance Program for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate). The Patient Assistance Program is designed to help patients with a diagnosis of pseudobulbar affect which meet established program criteria gain access to NUEDEXTA free of charge. "NUEDEXTA is the first and only FDA approved medication indicated for pseudobulbar affect....
(Ivanhoe Newswire)-- Elderly folks ages 65 and up who are living in a nursing home and taking certain antipsychotic medications for dementia could be hastening their death. The Harvard Medical School undertook the largest study ever among US nursing home residents, researchers looked at 75,445 older nursing home residents from 45 US states between 2001 and 2005. All nursing home residents studied were at least 65 years of age. Risks of mortality were examined over a 6 months period. The...
Research: Differential risk of death in older nursing home residents prescribed specific antipsychotic medications: Population-based cohort study Nursing home residents over the age of 65 who take certain antipsychotic medication for dementia are at an increased risk of death, suggests a research paper published today on bmj.com. The Harvard Medical School study, the largest ever undertaken among US nursing home residents, looked at 75,445 older nursing home residents from 45 US states...
ALISO VIEJO, Calif., Nov. 17, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA). Acceptance of the MAA confirms that the submission is sufficiently complete to permit a substantive review. NUEDEXTA was approved by the U.S. Food and Drug...
ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is considered the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis. Following are...
ALISO VIEJO, Calif., Aug. 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc (collectively "Par") and Actavis South Atlantic LLC and Actavis, Inc. (collectively "Actavis"). The lawsuits were filed in response to Abbreviated New Drug Applications ("ANDAs") filed by Par and Actavis. In their applications,...
ALISO VIEJO, Calif., July 26, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA). On July 22, 2011, company officials met with the European Medicines Agency (EMA) to discuss plans for filing a marketing authorization application (MAA) for NUEDEXTA for...
ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011. Avanir intends to vigorously enforce its intellectual property...
A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia (UEA).As part of the Medical Research Council's Cognitive Function and Ageing Studies (CFAS) project, the study is the first systematic investigation into the long term health impacts of 'anticholinergic activity' "“ a known potential side effect of many prescription and over the counter drugs which...
